# Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Source: https://onco.cc/trials/nct04588922/  
OnCo record `nct04588922` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Venetoclax and Azacitidine in advanced solid tumours, run by Sellas Life Sciences Group, now recruiting.

## Summary

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML is a phase 1/2 interventional study registered as NCT04588922 by Sellas Life Sciences Group, with 160 participants planned, started 2021-05-10 and due to reach its primary completion in 2026-12-30. Interventions recorded: SLS009, venetoclax and azacitidine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04588922
- Phase: 1/2
- Setting: A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination With Venetoclax and Azacitidine in Patients With Relapsed/Refractory Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Sponsor: Sellas Life Sciences Group
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT04588922: https://clinicaltrials.gov/study/NCT04588922

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [Galena Biopharma](https://onco.cc/companies/galena-biopharma/)

---
JSON: https://onco.cc/api/v1/entities/nct04588922.json